Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBITDA: 2013-2025

Historic EBITDA for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $3.7 million.

  • Theravance Biopharma's EBITDA rose 128.96% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.7 million, marking a year-over-year increase of 175.92%. This contributed to the annual value of -$46.9 million for FY2024, which is 16.21% up from last year.
  • Per Theravance Biopharma's latest filing, its EBITDA stood at $3.7 million for Q3 2025, which was down 93.33% from $54.8 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's EBITDA peaked at $916.6 million during Q3 2022, and registered a low of -$79.7 million during Q1 2021.
  • In the last 3 years, Theravance Biopharma's EBITDA had a median value of -$11.6 million in 2024 and averaged -$5.3 million.
  • Per our database at Business Quant, Theravance Biopharma's EBITDA spiked by 2,696.33% in 2022 and then slumped by 100.97% in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's EBITDA stood at -$56.2 million in 2021, then skyrocketed by 68.96% to -$17.4 million in 2022, then surged by 64.20% to -$6.2 million in 2023, then plummeted by 47.44% to -$9.2 million in 2024, then spiked by 128.96% to $3.7 million in 2025.
  • Its EBITDA stands at $3.7 million for Q3 2025, versus $54.8 million for Q2 2025 and -$13.6 million for Q1 2025.